EGFR Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance?


Journal Article

Anti-EGFR therapies have failed to improve survival for unselected patients with metastatic gastroesophageal cancer, but in a subset of patients, EGFR amplification may predict treatment benefit. Maron and colleagues report the clinical activity of anti-EGFR therapies in a cohort of patients with EGFR-amplified metastatic gastroesophageal cancer and utilize serial blood and tumor tissue collection to identify molecular drivers of treatment sensitivity and resistance. Their insights offer a path to overcome technical limitations associated with EGFR amplification and facilitate molecularly targeted therapeutic strategies. Cancer Discov; 8(6); 679-81. ©2018 AACRSee related article by Maron et al., p. 696.

Full Text

Duke Authors

Cited Authors

  • Strickler, JH

Published Date

  • June 2018

Published In

Volume / Issue

  • 8 / 6

Start / End Page

  • 679 - 681

PubMed ID

  • 29858225

Pubmed Central ID

  • 29858225

Electronic International Standard Serial Number (EISSN)

  • 2159-8290

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-18-0191


  • eng

Conference Location

  • United States